Vanda Pharmaceuticals (VNDA) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
X4 Pharmaceuticals (XFOR) has outperformed Vanda Pharmaceuticals (VNDA) over the past year, losing 16.0% versus a loss of 17.0%. Over five years, VNDA leads with a -75.4% price change compared with -98.2% for XFOR. X4 Pharmaceuticals is the larger company by market cap ($286.5 million vs $273.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VNDA | XFOR |
|---|---|---|
| Share price | $4.53 | $2.89 |
| Market cap | $273.59M | $286.53M |
| 1-day change | -0.11% | +3.58% |
| YTD return | -48.64% | -30.25% |
| 1-year return | -17.03% | -15.96% |
| 5-year return | -75.39% | -98.22% |
| P/E ratio (TTM) | — | 144.50 |
| Forward P/E | 22.63 | — |
| EPS (TTM) | $-4.63 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.94 | $4.83 |
| 52-week low | $4.27 | $2.70 |
| Distance from 52-week high | -54.48% | -40.17% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +159.67% | +301.38% |
| Average volume | 974.13K | 849.58K |
| Shares outstanding | 60.46M | 99.15M |
| Employees | 533 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
VNDA vs XFOR FAQ
Which is bigger, Vanda Pharmaceuticals or X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $286.53M compared with $273.59M for Vanda Pharmaceuticals (VNDA).
Which stock has performed better over the past year, VNDA or XFOR?
XFOR returned -15.96% over the past 12 months, compared with -17.03% for VNDA (price return, excluding dividends). Past performance does not predict future results.
Are Vanda Pharmaceuticals and X4 Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Vanda Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for X4 Pharmaceuticals.